Search details
1.
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Int J Cancer
; 154(6): 1043-1056, 2024 Mar 15.
Article
in English
| MEDLINE | ID: mdl-37994647
2.
Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma.
Clin Gastroenterol Hepatol
; 22(1): 72-80.e4, 2024 01.
Article
in English
| MEDLINE | ID: mdl-37442316
3.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int
; 44(1): 113-124, 2024 01.
Article
in English
| MEDLINE | ID: mdl-37789669
4.
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Liver Int
; 44(5): 1108-1125, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38517286
5.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res
; 54(4): 382-391, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-37983642
6.
Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.
J Gastroenterol Hepatol
; 2024 Apr 11.
Article
in English
| MEDLINE | ID: mdl-38602340
7.
Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
J Gastroenterol Hepatol
; 39(5): 949-954, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38291715
8.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology
; 101(9): 542-552, 2023.
Article
in English
| MEDLINE | ID: mdl-37552968
9.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology
; 101(4): 270-282, 2023.
Article
in English
| MEDLINE | ID: mdl-36455517
10.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology
; 101(10): 624-633, 2023.
Article
in English
| MEDLINE | ID: mdl-37307798
11.
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Oncology
; 101(5): 283-291, 2023.
Article
in English
| MEDLINE | ID: mdl-36657420
12.
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hepatol Res
; 53(10): 1031-1042, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37306040
13.
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatol Res
; 53(8): 737-748, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37020416
14.
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol Hepatol
; 38(8): 1389-1397, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37231943
15.
Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus.
J Viral Hepat
; 29(10): 919-929, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35790055
16.
International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients.
J Viral Hepat
; 29(9): 807-816, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35657138
17.
Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.
Oncology
; 100(2): 65-73, 2022.
Article
in English
| MEDLINE | ID: mdl-34844247
18.
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Oncology
; 100(12): 645-654, 2022.
Article
in English
| MEDLINE | ID: mdl-36103846
19.
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.
Hepatol Res
; 52(9): 773-783, 2022 Sep.
Article
in English
| MEDLINE | ID: mdl-35633504
20.
Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.
Hepatol Res
; 52(3): 235-246, 2022 Mar.
Article
in English
| MEDLINE | ID: mdl-34861090